Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.

Hexahydrobenzo[f]quinolines are effective at blocking the enzyme 5α-reductase.

Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.

The new delivery system could improve pain and inflammation relief in gout.

JAK/STAT1 pathway causes hair loss during chemotherapy by reducing Shh in hair follicles.

Cyclosporin promotes hair growth by boosting cell growth and reducing cell death.

Six existing drugs may help block virus entry in COVID-19.

A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.

A new gene mutation linked to KID syndrome was found, expanding genetic knowledge.

JAK inhibitors show promise in treating skin conditions like eczema, hair loss, and vitiligo but need more safety research.

Blocking the NOTCH pathway can prevent fibrosis in systemic sclerosis.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

Tyrosine kinases are important in skin autoimmune diseases and could be targets for new treatments.

Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.

Effective management of side effects is crucial for safe use of sacituzumab govitecan in advanced breast cancer treatment.

New JAK inhibitor drugs show promise for treating skin diseases but need more research on safety and effectiveness.

These new skin treatments are safer and more effective with minimal side effects.

Scientists found new, better-working inhibitors for a hormone-related enzyme.

Taking riboflavin and eating less lysine can help some people with a specific genetic disorder avoid brain damage.

Potassium channel openers show promise for treating heart disease and other conditions, but more research is needed to fully understand their effects and safety.

Brepocitinib improves cicatricial alopecia and reduces key immune markers.

RSPO1 could help create new diabetes treatments by increasing pancreatic β cells.

Greenly synthesized silver nanoparticles from lentils show strong anticancer and antimicrobial effects.

Combining MMP-9 and JAK inhibitors can effectively prevent skin depigmentation in vitiligo.

The new assay can help develop products for hair re-growth.

The new Brigatinib nanocarrier is more effective against lung cancer cells than the free drug.

Blocking casein kinase 1 in skin cells can help melanocyte precursors move better, potentially helping with conditions like vitiligo or gray hair.

The research shows how certain drug molecules form stable structures with polymers, which could help create new drug forms.

ETS2 is crucial in squamous cell carcinoma development and could be a therapeutic target.